Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...

The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...

Datopotamab deruxtecan indicated for patients ineligible for immunotherapy ...

The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with ...

When Chase Johnson was 31, her dog began acting strange. He was anxious, wouldn’t leave her side and, one day, pushed his nose into the side of her breast. Johnson felt a hard lump. “I wasn’t someone ...

Hearing the words “triple-negative breast cancer” (TNBC) can be overwhelming. It’s a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular ...

Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

"Triple-negative breast cancers are cancer cells that lack three receptors targeted by current chemotherapy regimens. Because of this lack of receptors, common cancer drugs can't 'find' the cells, and ...

Triple Negative Breast Cancer (TNBC) is one of the most aggressive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...